Retinopathy of Prematurity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major retinopathy of prematurity markets are expected to exhibit a CAGR of 5.1% during 2024-2034.
The retinopathy of prematurity market has been comprehensively analyzed in IMARC's new report titled "Retinopathy of Prematurity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Retinopathy of prematurity (ROP) refers to a potentially sight-threatening condition that primarily affects premature infants. It arises when the blood vessels in the retina, the light-sensitive cell at the back of the eye, develop abnormally due to premature birth and incomplete retinal vascularization. This disease can also lead to vision impairment or even blindness in severe cases. The symptoms of the ailment might not be noticeable in the early stages, but as the condition progresses, patients might experience abnormal eye movements, unequal pupil size, and a white or grayish appearance in the pupil. The diagnosis of ROP is typically made through regular eye examinations performed by a pediatric ophthalmologist. These tests involve dilating the pupils and using specialized instruments to visualize the retina's blood vessels. The healthcare provider monitors the progression of the disease and determines the appropriate treatment, if necessary, based on the severity of the condition.
The inflating prevalence of premature birth, leading to incomplete vascularization and abnormal development of retinal blood vessels due to imbalances in certain growth factors within the eyes, is primarily driving the retinopathy of prematurity market. In addition to this, the increasing utilization of efficacious treatments, such as laser therapy, cryotherapy, anti-VEGF injections, etc., to manage and arrest the progression of the condition is also creating a positive outlook for the market. Moreover, the widespread adoption of routine screening in neonatal intensive care units (NICUs), since early detection is paramount for timely intervention and preventing permanent visual impairment, is further propelling the market growth. Apart from this, the rising usage of vitrectomy and scleral buckling surgical procedures, which target detached retinas by either removing the vitreous gel or placing a flexible band around the eye, respectively, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive care practices, encompassing measures to create a conducive environment for preterm infants' overall growth and organ maturation, is also augmenting the market growth. Furthermore, the escalating demand for stem cell therapies, which focus on the potential regeneration of damaged retinal tissues by introducing precursor cells, is expected to drive the retinopathy of prematurity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the retinopathy of prematurity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for retinopathy of prematurity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinopathy of prematurity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the retinopathy of prematurity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the retinopathy of prematurity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current retinopathy of prematurity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the retinopathy of prematurity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the retinopathy of prematurity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the retinopathy of prematurity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of retinopathy of prematurity across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinopathy of prematurity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinopathy of prematurity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with retinopathy of prematurity across the seven major markets?
What is the size of the retinopathy of prematurity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of retinopathy of prematurity?
What will be the growth rate of patients across the seven major markets?
Retinopathy of Prematurity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for retinopathy of prematurity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the retinopathy of prematurity market?
What are the key regulatory events related to the retinopathy of prematurity market?
What is the structure of clinical trial landscape by status related to the retinopathy of prematurity market?
What is the structure of clinical trial landscape by phase related to the retinopathy of prematurity market?
What is the structure of clinical trial landscape by route of administration related to the retinopathy of prematurity market?
The retinopathy of prematurity market has been comprehensively analyzed in IMARC's new report titled "Retinopathy of Prematurity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Retinopathy of prematurity (ROP) refers to a potentially sight-threatening condition that primarily affects premature infants. It arises when the blood vessels in the retina, the light-sensitive cell at the back of the eye, develop abnormally due to premature birth and incomplete retinal vascularization. This disease can also lead to vision impairment or even blindness in severe cases. The symptoms of the ailment might not be noticeable in the early stages, but as the condition progresses, patients might experience abnormal eye movements, unequal pupil size, and a white or grayish appearance in the pupil. The diagnosis of ROP is typically made through regular eye examinations performed by a pediatric ophthalmologist. These tests involve dilating the pupils and using specialized instruments to visualize the retina's blood vessels. The healthcare provider monitors the progression of the disease and determines the appropriate treatment, if necessary, based on the severity of the condition.
The inflating prevalence of premature birth, leading to incomplete vascularization and abnormal development of retinal blood vessels due to imbalances in certain growth factors within the eyes, is primarily driving the retinopathy of prematurity market. In addition to this, the increasing utilization of efficacious treatments, such as laser therapy, cryotherapy, anti-VEGF injections, etc., to manage and arrest the progression of the condition is also creating a positive outlook for the market. Moreover, the widespread adoption of routine screening in neonatal intensive care units (NICUs), since early detection is paramount for timely intervention and preventing permanent visual impairment, is further propelling the market growth. Apart from this, the rising usage of vitrectomy and scleral buckling surgical procedures, which target detached retinas by either removing the vitreous gel or placing a flexible band around the eye, respectively, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive care practices, encompassing measures to create a conducive environment for preterm infants' overall growth and organ maturation, is also augmenting the market growth. Furthermore, the escalating demand for stem cell therapies, which focus on the potential regeneration of damaged retinal tissues by introducing precursor cells, is expected to drive the retinopathy of prematurity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the retinopathy of prematurity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for retinopathy of prematurity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinopathy of prematurity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the retinopathy of prematurity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the retinopathy of prematurity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current retinopathy of prematurity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the retinopathy of prematurity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the retinopathy of prematurity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the retinopathy of prematurity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of retinopathy of prematurity across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinopathy of prematurity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinopathy of prematurity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with retinopathy of prematurity across the seven major markets?
What is the size of the retinopathy of prematurity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of retinopathy of prematurity?
What will be the growth rate of patients across the seven major markets?
Retinopathy of Prematurity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for retinopathy of prematurity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the retinopathy of prematurity market?
What are the key regulatory events related to the retinopathy of prematurity market?
What is the structure of clinical trial landscape by status related to the retinopathy of prematurity market?
What is the structure of clinical trial landscape by phase related to the retinopathy of prematurity market?
What is the structure of clinical trial landscape by route of administration related to the retinopathy of prematurity market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RETINOPATHY OF PREMATURITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RETINOPATHY OF PREMATURITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RETINOPATHY OF PREMATURITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 RETINOPATHY OF PREMATURITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RETINOPATHY OF PREMATURITY - UNMET NEEDS
10 RETINOPATHY OF PREMATURITY - KEY ENDPOINTS OF TREATMENT
11 RETINOPATHY OF PREMATURITY - MARKETED PRODUCTS
11.1 List of Retinopathy of Prematurity Marketed Drugs Across the Top 7 Markets
11.1.1 Lucentis (Ranibizumab) - Genentech/Novartis Ophthalmics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Eylea (Aflibercept) - Bayer/Regeneron Pharmaceuticals/Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RETINOPATHY OF PREMATURITY - PIPELINE DRUGS
12.1 List of Retinopathy of Prematurity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. RETINOPATHY OF PREMATURITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RETINOPATHY OF PREMATURITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RETINOPATHY OF PREMATURITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Retinopathy of Prematurity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Retinopathy of Prematurity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Retinopathy of Prematurity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Retinopathy of Prematurity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Retinopathy of Prematurity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Retinopathy of Prematurity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Retinopathy of Prematurity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Retinopathy of Prematurity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Retinopathy of Prematurity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Retinopathy of Prematurity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Retinopathy of Prematurity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Retinopathy of Prematurity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Retinopathy of Prematurity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Retinopathy of Prematurity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Retinopathy of Prematurity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Retinopathy of Prematurity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Retinopathy of Prematurity - Access and Reimbursement Overview
16 RETINOPATHY OF PREMATURITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RETINOPATHY OF PREMATURITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RETINOPATHY OF PREMATURITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RETINOPATHY OF PREMATURITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RETINOPATHY OF PREMATURITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RETINOPATHY OF PREMATURITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 RETINOPATHY OF PREMATURITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RETINOPATHY OF PREMATURITY - UNMET NEEDS
10 RETINOPATHY OF PREMATURITY - KEY ENDPOINTS OF TREATMENT
11 RETINOPATHY OF PREMATURITY - MARKETED PRODUCTS
11.1 List of Retinopathy of Prematurity Marketed Drugs Across the Top 7 Markets
11.1.1 Lucentis (Ranibizumab) - Genentech/Novartis Ophthalmics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Eylea (Aflibercept) - Bayer/Regeneron Pharmaceuticals/Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RETINOPATHY OF PREMATURITY - PIPELINE DRUGS
12.1 List of Retinopathy of Prematurity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. RETINOPATHY OF PREMATURITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RETINOPATHY OF PREMATURITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RETINOPATHY OF PREMATURITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Retinopathy of Prematurity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Retinopathy of Prematurity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Retinopathy of Prematurity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Retinopathy of Prematurity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Retinopathy of Prematurity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Retinopathy of Prematurity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Retinopathy of Prematurity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Retinopathy of Prematurity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Retinopathy of Prematurity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Retinopathy of Prematurity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Retinopathy of Prematurity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Retinopathy of Prematurity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Retinopathy of Prematurity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Retinopathy of Prematurity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Retinopathy of Prematurity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Retinopathy of Prematurity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Retinopathy of Prematurity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Retinopathy of Prematurity - Access and Reimbursement Overview
16 RETINOPATHY OF PREMATURITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RETINOPATHY OF PREMATURITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RETINOPATHY OF PREMATURITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
